Navigation Links
AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Date:4/30/2008

monstrated in Phase 2 studies to provide fast and long-lasting relief of BPH symptoms while being well tolerated, with a low incidence of sexual side effects. Both BPH studies of cetrorelix presented in Milan were chaired by Prof. Frans M.J. Debruyne, M.D., Ph.D., former President of EAU, now Chairman and CEO of Andros Men's Health Institutes in The Netherlands.

Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovarian stimulation/assisted reproductive technologies) in Europe, the U.S. and Japan. It was launched on the market through Serono (now Merck Serono) in the United States, Europe and in several other countries, as well as in Japan through Shionogi.

About the Cetrorelix Phase 3 Program in BPH

Cetrorelix pamoate is being studied in three Phase 3 trials which will include approximately 1,500 men with symptomatic BPH in the United States, Canada and Europe. One Phase 3 efficacy trial, primarily in the United States and Canada and with additional sites in Europe, involves approximately 600 patients (which are fully enrolled) and is being led by Herbert Lepor, M.D., Professor and Martin Spatz Chairman of Urology, New York University School of Medicine, New York. In the trial, patients enter a no-treatment run-in observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (I-PSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients will receive cetrorelix by IM injection at W
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Announces Changes to its Management Team
4. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
5. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
6. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
7. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... MAR, Calif. , Sept. 30, 2014 ... for women,s health announces its receipt of a patent ... FemmyCycle menstrual cup has also received FDA clearance in ... Canada, and the CE in Europe. This patent is related ... conjunction with this issuance, the company is releasing FemmyCycle ...
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Back in the ... 500 square feet. per employee, which included space for circulation ... then.” says Jeff Howell, partner at Nidea Corporate Real ... in Toronto. “By the year 2000, however, 250 square ... seeing that number come down to 175 to 225 square ...
(Date:9/29/2014)... , Sept. 29, 2014  Ten of ... fields of cartilage repair, regeneration, allograft reconstruction and ... around the world gathered to discuss the future ... Institute of Regenerative Medicine symposium, Cartilage Regeneration: ... Topics included Orthopedic Biosurgery, Minced Juvenile Allograft, and ...
Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... LOUIS, Aug. 27 Missouri Coalition for,Lifesaving Cures ... far-,reaching initiative petition filed last week by opponents ... worded and scientifically unsound that it,would exclude Missourians ... syndromes from its definition of "human." In ...
... Drug Royalty LP 2 (DRC) announced,today the ... worldwide,royalty interest in PEG-INTRON for $92.5M. DRC will ... certain royalty recognition levels be met.,PEG-INTRON (peginterferon alpha-2b), ... is marketed worldwide by Schering-Plough Corporation (SGP). ...
... 27 NovaQuest has,made a strategic investment ... specializing in respiratory,disorders. The investment was part ... million) in the Montreal-based company. Last ... partnering group,of Quintiles Transnational, helps TOPIGEN accelerate ...
Cached Biology Technology:New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human 2Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN) 2NovaQuest Advances 'Virtual Development' Model With Strategic Investment in TOPIGEN Pharmaceuticals 2
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... of their woody material, could be the key to a ... who add that the approach could also help turn agricultural ... component of woody plant material, is woven in with cellulose ... of wind and microbial attack. However, this protective barrier or ...
... NEW YORK, Dec. 22, 2008 NYU Langone Medical Center ... La Jolla, Calif., have discovered an unexpected cause for the ... of the central nervous system, according to a study published ... new way of thinking about how the human immune system ...
... for humans, Plasmodium falciparum , has been linked ... fairly isolated on the malarial family treeuntil now. A ... Genomics at the American Museum of Natural History reveals ... close evolutionary relationship with P. falciparum and ...
Cached Biology News:Modified plants may yield more biofuel 2Peering inside the skull of a mouse to solve meningitis mystery 2Peering inside the skull of a mouse to solve meningitis mystery 3African thicket rat malaria linked to virulent human form 2
...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... Tecans open platform for clinical diagnostic applications, ... performance in the clinical diagnostic and blood ... barcode reading and sample traceability as standard ... complies with the IVD-Directive* established in the ...
Biology Products: